Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Open Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination With Lenalidomide Versus Rituximab in Combination With Lenalidomide Therapy in Relapsed/Refractory Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)

Next Previous
Trial Profile

A Phase 3, Open Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination With Lenalidomide Versus Rituximab in Combination With Lenalidomide Therapy in Relapsed/Refractory Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Odronextamab (Primary) ; Lenalidomide; Rituximab
  • Indications Follicular lymphoma; Marginal zone B-cell lymphoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms Olympia-5
  • Sponsors Regeneron Pharmaceuticals

Most Recent Events

  • 13 Nov 2025 According to Regeneron Pharmaceuticals media release, data from the trial will be presented at the American Society of Hematology (ASH) 2025 Annual Meeting, taking place from December 6-9 in Orlando, FL.
  • 29 Aug 2024 Planned End Date changed from 4 Oct 2029 to 23 Jan 2029.
  • 29 Aug 2024 Planned primary completion date changed from 4 Oct 2029 to 23 Jan 2029.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top